Olvance H 40 Tablet is a combination antihypertensive medication containing Hydrochlorothiazide 12.5 mg and Olmesartan Medoxomil 40 mg, indicated for the treatment of hypertension. Olmesartan Medoxomil, an angiotensin II receptor antagonist, selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide, a thiazide diuretic, promotes sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to a decrease in plasma volume and peripheral resistance. The combination of these agents provides complementary mechanisms for effective blood pressure control, reducing the risk of cardiovascular events such as stroke and myocardial infarction. Olvance H 40 is typically prescribed when monotherapy with either agent is insufficient to achieve target blood pressure levels. Patients should be monitored for electrolyte imbalances, renal function, and blood pressure response during therapy. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in pregnancy due to potential fetal toxicity. Adverse effects may include dizziness, hypotension, hyperkalemia, and electrolyte disturbances. Regular follow-up and adherence to prescribed dosage are essential for optimal therapeutic outcomes.